LORA DILLMAN: Open Payments
NPI 1396526992 · KOKOMO, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,114 in 132 payments from 24 companies in 2025. Trend: 2023 $36 · 2024 $1,804 · 2025 $2,114
Food & beverage: $2,114
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 27 | $405 |
| ABBVIE INC. | 25 | $276 |
| AstraZeneca Pharmaceuticals LP | 10 | $219 |
| PFIZER INC. | 12 | $205 |
| Bayer Healthcare Pharmaceuticals Inc. | 14 | $198 |
| Lilly USA, LLC | 8 | $167 |
| Axsome Therapeutics, Inc. | 3 | $90 |
| Amgen Inc. | 5 | $83 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 3 | $52 |
Products named: Ozempic, Kerendia, Wegovy, VRAYLAR, MOUNJARO, NURTEC ODT, Auvelity, FARXIGA.
Industry payments across IN — which companies pay providers there.
